Join our community of smart investors

Dr Martens under margin pressure

Shares given a shoeing as the cash margin margin contracts
November 24, 2022
  • Cash profits in line with consensus
  • Direct-to-consumer sales growth slows

It’s so obvious that it hardly bears repeating, but the outlook for consumer retail stocks has darkened due to falling discretionary incomes. So, although Dr Martens (DOCS), the producer of the eponymous boot range, is no longer hobbled by Covid-19-related supply challenges, slower-than-expected growth in its direct-to-consumer (DTC) arm saw its market valuation plummet on results day.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in